Primary Objective: Determine blood concentrations of two formulations of REGN2222 Secondary Objective: Assess safety and tolerability of REGN2222
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
28
Unnamed facility
Daytona Beach, Florida, United States
Unnamed facility
Evansville, Indiana, United States
Serum REGN2222 concentration-time curve (AUC)
Time frame: Day 1 to Day 148 (end of study)
Peak REGN2222 concentration (Cmax)
Time frame: Day 1 to Day 148 (end of study)
Treatment-emergent adverse events (TEAEs) from baseline to the end of the study
Time frame: Day 1 to Day 148 (end of study)
Presence or absence of anti-drug antibody (ADA)
Time frame: Day 1 to Day 148 (end of study)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.